Library Header Image
LSE Research Online LSE Library Services

VP164: Applying HTA to pharmacy: the Italian-Medicine-Use-Review-HTA

Tinelli, Michela ORCID: 0000-0002-8816-4389, Manfrin, Andrea, Knapp, Martin ORCID: 0000-0003-1427-0215 and Mandelli, A. (2017) VP164: Applying HTA to pharmacy: the Italian-Medicine-Use-Review-HTA. In: HTAi 2017 Annual Meeting, 2017-06-17 - 2017-06-21, Rome, Italy, ITA. (Submitted)

Full text not available from this repository.


Introduction: There is a lack of Health-Technology-Assessment (HTA) tools in pharmacy practice and the collection of real-world-evidence (RWE) in community pharmacy to populate longer-term-disease-progression-modelling (1). This project is looking at the development and application of a novel Patient-Reported-Outcome- Measure (PROM) in community pharmacy that can enable: the evaluation of the quality of care delivered from the patient perspective in terms of economic impact, patient health outcomes and ‘utilities’; the collection of RWE and evaluate long-term effect of care; to provide different stakeholders with unique evidence-based information that help formulate health policies in community pharmacy that are safe, effective, patient-focused and cost-effective, balancing access to innovation and cost containment. Methods: Evidence from the Italian-Medicine-Use-Review (I-MUR) trial (2) showed that the I-MUR intervention provided by community pharmacists to asthma patients is effective, cost-saving and cost-effective (3). The trial allowed to model a framework (I-MUR-HTA) that would enable to routinely deliver the intervention, but also collect and analyse PROM data on its clinical-effectiveness, quality-of-life and cost-effectiveness. I-MUR-HTA was discussed within three expert-panel discussions including policy-makers, commissioners, academics, healthcare-professionals and patient-representatives in Italy, United Kingdom and Europe. Current plan include testing the use of the tool in the real world environment. Results: Evidence collected from the panel discussions confirmed that I-MUR-HTA evidence-based information is relevant to meet current National-Health-Care-System plans and this is what is needed to support the evaluation of innovative effective and cost-effective health policies and promote their implementation across nations. Current Italian law on pharmacy services provides the appropriate institutional framework to regulate the introduction of I-MUR-HTA across the territory. Its implementation is underway and a real-world pilot is planned to take place in Italy. Conclusions: I-MUR-HTA appears to be an innovative tool to promote active patient involvement into policy-decision-making and pharmacy-service.

Item Type: Conference or Workshop Item (Paper)
Official URL:
Additional Information: © 2017 The Authors
Divisions: Personal Social Services Research Unit
LSE Health
Subjects: R Medicine > RS Pharmacy and materia medica
Date Deposited: 02 Mar 2018 15:13
Last Modified: 16 May 2024 11:11

Actions (login required)

View Item View Item